Medivation Inc (MDVN.O), which expects key data this year from a pivotal trial of its experimental prostate cancer drug, believes the medicine could have competitive advantages over current therapies. The company earlier this year rejigged its Phase 3 trial of the drug, MDV3100, to trigger an interim analysis during 2011. The move followed successful pivotal trial results for Johnson & Johnson’s (JNJ.N) prostate cancer drug Zytiga, or abiraterone, which was approved by U.S. regulators in April to treat cancer that has spread and is no longer held back by hormone-deprivation therapy.
